Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290523 · ClinicalTrials.gov registry record · NA
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01290523 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 14 participants.
The verdict
NCT01290523, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a prospective pilot study that will document the clinical experience of 30 patients with unresectable hepatocellular carcinoma undergoing liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere®).
Interventions
- DEVICE Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290523
The ClinicalTrials.gov registry entry for NCT01290523 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere) is the first listed.
NCT01290523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290523 about?
NCT01290523 is a clinical study titled "Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma". This is a prospective pilot study that will document the clinical experience of 30 patients with unresectable hepatocellular carcinoma undergoing liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere®).
What is the current status of trial NCT01290523?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2010-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01290523?
The interventions under investigation include: Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere) (DEVICE).
Who is sponsoring clinical trial NCT01290523?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.